Drugs / Platelet Poor Plasma
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03120988 | Jul 2016 → Jun 2017 | osteoarthritis, knee | Regenexx, LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07513142 | Mar 2026 → Jun 2027 expected | musculoskeletal system disorder | Andrews Research & Education Foundation | Enrolling by invitation | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05287867 | May 2022 → Dec 2026 expected | lumbar disk degenerative disorder | Regenexx, LLC | Recruiting | No outcome recorded |
| — | NCT03618979 | May 2019 → Jun 2022 | — | Regenexx, LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Platelet Poor Plasma | “A Randomized Controlled Trial to Assess the Effects of Autologous Platelet Rich Plasma, Platelet Lysate, and Platelet Poor Plasma on Atrophied Multifidus Muscles in Patients...” NCT03618979 ↗ |
| Known as | PPP | “The purpose of this study is to compare the number of days it takes for a sport participant to return to play between ultrasound guided intramuscular corticosteroid injections...” NCT07513142 ↗3“Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)” NCT03618979 ↗ “Lavage with Platelet Poor Plasma (PPP)” NCT03120988 ↗ “Platelet Poor Plasma (PPP)” NCT05287867 ↗ |
| Route | Other | “introducing a solution of platelet poor plasma into the knee joint” NCT03120988 ↗ |